Epigenetic considerations for endometrial cancer prevention, diagnosis and treatment

X Clare Zhou1, Sean C Dowdy, Karl C Podratz

  • 1Department of Obstetrics and Gynecology, Mayo Clinic and Foundation, Rochester, MN 55905, USA.

Gynecologic Oncology
|August 19, 2007
PubMed

Insights

Aberrant DNA methylation is a key molecular change in endometrial cancer. Epigenetic strategies show promise for diagnosis, treatment, and preventing cancer by targeting DNA methylation and gene expression.

Area of Science:

  • Oncology
  • Epigenetics
  • Molecular Biology

Background:

  • Aberrant DNA methylation is a hallmark of many cancers, including endometrial cancer.
  • Hypermethylation and gene silencing affect critical genes like those for steroid receptors, tumor suppressors, and DNA repair.
  • Distinct DNA methylation patterns in type I and type II endometrial cancers indicate different epigenetic landscapes and tumor development pathways.

Purpose of the Study:

  • To review the implications of recent epigenetic findings for endometrial cancer.
  • To explore the potential of epigenetics in cancer prevention, diagnosis, and treatment.

Main Methods:

  • Review of current literature on epigenetics in endometrial cancer.
  • Analysis of DNA methylation patterns and their role in tumorigenesis.
  • Evaluation of epigenetic modification reagents and their therapeutic potential.

Main Results:

  • DNA methylation patterns differ between type I and type II endometrial cancers.
  • DNA methylation-based assays may serve as valuable diagnostic tools.
  • Epigenetic therapies, including inhibitors of DNA methyltransferase and histone deacetylase, show therapeutic promise.

Conclusions:

  • Epigenetic alterations are crucial in endometrial cancer development.
  • Epigenetic approaches offer novel strategies for endometrial cancer prevention, diagnosis, and treatment.
  • Reactivating progesterone receptor epigenetically can re-sensitize advanced endometrial cancers to therapy.